Urothelial Cancer

Antonio Cigliola, MD, discusses the phase 2 SURE-01 study of neoadjuvant sacituzumab govitecan in muscle-invasive bladder cancer.

IDE937 produced responses in patients with advanced urothelial cancer or non–small cell lung cancer harboring MTAP deletions.

Rohan Garje, MD, discusses the benefits of a multimodal approach for patients with small cell bladder cancer.

Brian I. Rini, MD, FASCO, on findings from a biomarker analysis of the KEYNOTE-426 trial of pembrolizumab/axitinib vs sunitinib in renal cell carcinoma.

Antonio Cigliola, MD, discusses the evaluation of neoadjuvant sacituzumab govitecan in patients with muscle-invasive bladder cancer.

Laurence Albigès, MD, PhD, discusses the potential predictive and prognostic value of circulating KIM-1 in patients with renal cell carcinoma.

Tazemetostat plus pembrolizumab was tolerable in platinum-exposed or -ineligible advanced urothelial carcinoma.

The EMA's CHMP has adopted a positive opinion regarding erdafitinib in patients with FGFR3+ unresectable or metastatic urothelial carcinoma.

Antonio Cigliola, MD, discusses interim efficacy data from the SURE-01 study investigating neoadjuvant sacituzumab govitecan in patients with MIBC.

Bradley McGregor, MD, on the ongoing evaluation of sacituzumab govitecan plus enfortumab vedotin with or without pembrolizumab in urothelial carcinoma.

Perioperative durvalumab demonstrated a statistically significant improvement in EFS and OS in muscle-invasive bladder cancer.

David Braun, MD, PhD, discusses findings from the molecular analysis of the HCRN GU16-260-Cohort A study.

Fernando C. Maluf, MD, PhD discusses the efficacy of platinum-based chemotherapy plus pembrolizumab in advanced penile squamous cell carcinoma.

Michael Serzan, MD, discusses the use of botensilimab/balstilimab in the treatment of patients with advanced renal cell carcinoma.

Roger Li, MD, discusses patient outcomes from the KEYNOTE-057 trial in BCG–unresponsive, high-risk non–muscle-invasive bladder cancer.

Joaquim Bellmunt, MD, PhD discusses findings from a post-hoc analysis for avelumab maintenance in advanced urothelial carcinoma with low tumor burden.

Petros Grivas, MD, PhD, and Chandler H. Park, MD, FACP, discuss key updates in genitourinary cancer on OncLive News Network: On Location.

Laurence Albigès, MD, PhD discusses a biomarker analysis which evaluated the presence of circulating KIM-1 in patients with renal cell carcinoma.

Joaquim Bellmunt, MD, PhD, discusses the predictive value of H3K27ac epigenomic and single-cell transcriptional profiling in urothelial cancer.

Partition overall survival data indicated that nivolumab plus cabozantinib extended treatment-free survival vs sunitinib in advanced renal cell carcinoma.

Cretostimogene grenadenorepvec plus pembrolizumab sustains high CR rate in NMIBC according to the phase 2 CORE-001 trial.

Bernard H. Bochner, MD, FACS discusses genomic complexity and heterogeneity in bladder cancer tumors.

Bradley McGregor, MD, discusses the investigation of sacituzumab govitecan plus enfortumab vedotin in metastatic urothelial cancer.

Bradley McGregor, MD, discusses the DAD-IO trial of sacituzumab govitecan, enfortumab vedotin, and pembrolizumab in metastatic urothelial cancer.

The addition of avelumab to cisplatin-based chemotherapy led to high event-free survival and overall survival rates in patients with muscle-invasive urothelial carcinoma.

Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease (MRD), disease recurrence, and benefit from adjuvant atezolizumab (Tecentriq) in patients with renal cell carcinoma (RCC) at increased risk of recurrence.

Enfortumab vedotin plus pembrolizumab did not negatively affect quality of life in patients with advanced urothelial carcinoma.

Using CD8-positive, PD-1-positive, TIM3-negative, and LAG3-negative TILs as a biomarker was not associated with improved clinical outcomes for patients with mccRCC treated with nivolumab plus ipilimumab.

Neoadjuvant sacituzumab govitecan demonstrated efficacy in patients with muscle-invasive bladder cancer, but its future role in the space is uncertain.